|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 302.40 SEK | -1.43% |
|
+1.20% | -2.70% |
| 12/03 | Scandibio recruits 200 patients for Phase 3 Alzheimer's study | FW |
| 11/03 | BioArctic partner to present long-term lecanemab data at AD/PD conference | FW |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| -.--% | 0.66% | 26.64x | 14.05x | 12.46x | 20.89x | 20.65x | 284.39Cr | ||
| 1.02% | 1.12% | 33.07x | 3.45x | 4.92x | 16.5x | 24.16x | 4.28TCr | ||
| -.--% | -.--% | 51.27x | 6.61x | 4.42x | 29.75x | 37.55x | 3.15TCr | ||
| 0.35% | 0.35% | 54.26x | 2.59x | 11.14x | 30.96x | 39.97x | 3TCr | ||
| -.--% | -.--% | 19.97x | 3.58x | 2.36x | 10.18x | 15.43x | 2.77TCr | ||
| -.--% | -.--% | -12.38x | 16.77x | 320.84x | -10.44x | -10.35x | 1.88TCr | ||
| -.--% | -.--% | 43.12x | 159.3x | 8.22x | 25.82x | 33.47x | 1.39TCr | ||
| -.--% | -.--% | 26.34x | 13.13x | 4.19x | 19.06x | 19.99x | 1.28TCr | ||
| 1.23% | 1.37% | 20.1x | 2.28x | 1.87x | 8.16x | 12.57x | 1.24TCr | ||
| -.--% | -.--% | -17.61x | -48.43x | 13.71x | -19.11x | -17.59x | 1.18TCr | ||
| -.--% | -.--% | -31.26x | 21.06x | 6x | 147.84x | -290.99x | 893.51Cr | ||
| 0.5% | 0.28% | 20.7x | 2.31x | 4.23x | 11.5x | 14.26x | 836.66Cr | ||
| -.--% | -.--% | -19.5x | 7.28x | 1102.56x | -16.23x | -16.04x | 818.68Cr | ||
| 0.63% | 0.63% | 40.46x | 3.66x | 6.44x | 18.03x | 19.85x | 795.56Cr | ||
| -.--% | -.--% | 19.96x | - | - | - | - | 765.3Cr | ||
| -.--% | -.--% | 15.21x | 0.8x | 1.31x | 6.66x | 7.42x | 750.85Cr | ||
| 0.72% | 0.89% | 28.35x | 3.3x | 3.59x | 14.72x | 23.15x | 684.36Cr | ||
| Average | 0.26% | 0.31% | 18.75x | 13.23x | 94.27x | 19.64x | -4.16x | 1.53TCr | |
| Weighted average by Cap. | 0.32% | 0.35% | 25.19x | 12.09x | 64.92x | 18.93x | 8.46x |
- Stock Market
- Equities
- BIOA B Stock
- Sector BioArctic AB
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















